Trial Profile
An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 06 Dec 2022
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary fibrosis; Pulmonary hypertension
- Focus Therapeutic Use
- Sponsors United Therapeutics Corporation
- 08 Nov 2022 Status changed from completed to discontinued.
- 19 Oct 2022 Results assessing the long term safety and tolerability of treprostinil in patients with PHA with interstitial lung disease, presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians.
- 14 Oct 2022 According to a United Therapeutics Corporation media release, long-term data from this trial will be presented at the CHEST 2022 Annual Meeting hosted by the American College of Chest Physicians.